

Financial Disclosures

The CONy Congress seeks to balance the important benefits of physician-industry relationships with the potential risk that the financial goals of the industry may conflict with the professional goals of CONy participants. In doing so, the CONy Congress recognizes that it has a profound duty to its participants, the larger medical community and the public to ensure the integrity of all of its scientific, educational, and advocacy activities and materials.

Educational Content Development

The CONy Congress requires all Program members and any others in a position to control the educational content to disclose any commercial financial interests prior to the development of the educational content. A process of resolution of conflict of interest is used for those members who do have financial interests related to the development of the content.

Program members who fail to provide financial disclosures are not permitted to participate in the development of educational content.

Committee & Faculty

The CONy Congress considers financial relationships to create actual conflicts of interest when Committee & Faculty or their immediate family (defined as spouse, domestic partner, parent, child or spouse of child, or sibling or spouse of sibling of the Committee & Faculty) have both a financial relationship with a commercial interest and the opportunity to affect the policy of the CONy Congress of CME about the products or services of that commercial interest. The potential for Presenter to maintaining or increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the CME – an incentive to insert commercial bias.

All Committee & Faculty of CME content should familiarize themselves with the policy of the CONy Congress of CME based on the CME provider of the Congress – the EACCME (<http://admin.uems.net/uploadedfiles/174.pdf>).

All CONy Faculty presenting CME are required to disclose to the activity audience the following information prior to beginning their presentation:

- Any relevant financial relationships a CME presenter has had with manufacturers of commercial ophthalmic products or providers of commercial ophthalmic services within the past 12 months. The CONy Congress defines "relevant" financial relationships as those with a commercial ophthalmic interest and the opportunity to affect the content of CME about the products or services of that commercial ophthalmic interest
- CME Committee & Faculty who report they have no known relevant financial relationships to disclose will declare "No Financial Relationships"

NOTE: All Committee & Faculty are required to report financial disclosures, using the codes below. An individual's financial disclosures for the 9th CONy Congress meeting are listed in this Section.

CONy Financial Disclosure Codes

Category	Code	Description
None	N	No financial relationships
Advisory Board	B	Member of a company advisory board, board of directors or other similar group
Lecture fees	L	Lecture fees, consultant fees, honoraria, travel fees or reimbursements when speaking at the invitation of a commercial entity for the past 1 year
Sponsored	S	Participation in a company sponsored speakers' bureau
Equity owner	O	Equity ownership/stock options
Grant support	G	Grant support, research support for the past 1 year (all sources) and all sources used for this project

Disclosure Information

Financial interest disclosures from program members and others in a position for control content

Committee and Faculty

Sabine Alam, UK

N

Panos Alexopoulos, Germany

N

Edson Amaro, Brazil

N

Frank Andrasik, USA

N

Elsa Azevedo, Portugal

N

Stavros Baloyannis, Greece

N

Peter Barsi, Hungary

N

Christoph Baumgartner, Austria

N

Bernhard Baune, Australia

N

Marcelo Bigal, USA

N

Heinrich Binder, Austria

N

Gyorgy Blaskó, Hungary

N

Ilan Blatt, Israel

L Upsher-Smith

Laszlo Bognar, Hungary

N

Hayrunnisa Bolay, Turkey

N

Michael Brainin, Austria

N

Herbert Budka, Austria

N

Roger Bullock, UK

N

Anca Dana Buzoianu, Romania

N

Jesse Cedarbaum, USA

S (*employed*) Biogen

Joab Chapman, Israel

G Merck Serono

G, L Teva

G, L Novartis

G, L Medison (Biogen)

Michael Chopp, USA

N

Cris Constantinescu, UK

G Bayer

G, L, S Biogen Idec

G Merck Serono

G, L Morphosys

G, L, S Novartis

G Roche

G Sanofi Pasteur

G MSD

G, L, S Teva

Robert Cowan, USA

G, L Allergan

L Avanir

L Nupathe

Lars Edvinsson, Sweden

N

Eva Feldman, USA

N

Andras Fogarasi, Hungary

N

Pedro Fonseca, Portugal

N

Mark Freedman, Canada

L, B Bayer Healthcare

L, B Biogen Idec

B Hoffman La-Roche

B Merck Serono

L Chugai

L EMD Canada

L, S Genzyme

L, B Novartis

B Opexa

L, B Sanofi Aventis

L Teva Canada Innovation

Robert Gabor Kiss, Hungary

L Bayer AG

L Biogen Ingelheim

L Pfizer

Elliott Gross, USA

N

Alla Guekht, Russia

G Ever NeuroPharma

G Takeda

Hans Hamburger, The Netherlands

N

Deiter Heiss, Germany

N

Martin Hofmann-Apiritus, Germany

N

Volker Hömberg, Germany

L Ever NeuroPharma

Zsolt Illes, Denmark

G, L Biogen Idec

L Sanofi Aventis

L Merck Serono

L Teva

L Novartis

Kurt Jellinger, Austria

N

Dimitrios Karussis, Israel

N

Peter Kempler, Hungary

L, B Worwag-Pharma Gmbh

Spiros Konitsiotis, Greece

L, S Novartis

L, S UCB

L, S Lundbeck

L, S Abbvie

Jose Miguel Lainez, Spain

G, S ATI

G, S Allergan

G Roche

G Boehringer Ingelheim

G Lupin Otsuka

G, S Electrocore

Adriaan A. Lammerstma,

The Netherlands

G, L Philips

G Avid

Hans Lassmann, Austria

L Teva

L Novartis

Stephanie Lenck, France

N

Claudia Lucchinetti, USA

G Department of Defense

G Novartis

G Alexion

Francesca Mangialasche, Sweden

N

Lefkos Middleton, UK

G, L Janssen

G, L Astra Zeneka

G Takeda

G Zinfandel

G UCB

G Abbott

Ron Milo, Israel

G, L Bayer

G, L, S Biogen Idec

L Genzyme

G, L Merck Serono

L Neuropharm

G, L, S Novartis

G, L Teva

Dimos Mitsikostas, Greece
G Biogen
L Merck Serono
L Genzyme-Sanofi
L Novartis
L Bayer
L Genesis Pharma
L Allergan
L Teva

Jay P. Mohr, USA
N

Laszlo Olah, Hungary
N

Victor Oliveira, Portugal
N

Celia Oreja-Guevara, Spain
N

Tiago Outeiro, Germany
N

Marco Pagani, Italy
N

Denes Pall, Hungary
N

Gyula Pánczél, Hungary
N

Robert Pernecky, UK
N

Marios Politis, UK
N

Uroš Rot, Slovenia
G, L Biogen Idec
L Novartis
L Bayer
L Merck Serono
L Teva

Judit Sandor, Hungary
G Nerri Fp7

Ilana Schlesinger, Israel
N

Jean Schoenen, Belgium
G, L Electrocore
G, L Cefaly Technology
L Allergan
L ATI
L Gedeon Richter
L St Jude Medical
L Medtronic

Krzysztof Selmaj, Sweden
L, S Biogen
L, S Bayer
L, S Genzyme
L, S Novartis
L, S Receptos
L, S Roche
L, S Synthon
L, S Teva

Ashfaq Shuaib, Canada
N

Christian Stapf, France
N

Thorsten Steiner, Germany
L, S Bayer
L, S Boehringer
L, S BMS Pfizer

Ewa Stelmasiak, Poland
N

Erwin Stolz, Germany
G Boehringer Ingelheim
G Bracco
G Philips
G Schering

Johannes Streffer, Belgium
N

Jonathan Streifler, Israel
N

Olaf Stuve, USA
G Teva
G Opexa Therapeutics

William Theodore, USA
N

Babek Tousi, USA
G Avanir
G Avid
G, L Grifols
L Eli Lilly
G Lundbeck

Manjari Tripathi, India
N

Tamas Várkonyi, Hungary
N

Patrick Vermersch, France
G, L Merck Serono
G, L Bayer
G, L Novartis
L Biogen Idec
L Almirall
L Genzyme-Sanofi
L Teva

Jens Volkmann, Germany
G, L BSCI
G, L Medtronic
L St Jude
L Teva
L UCB
L Novartis
L Allergan
L Merz

Heinz Wiendl, Germany
G Bayer Healthcare
G, L Biogen Idec
G, L Merck Serono
G, L Novartis
G Sanofi Aventis/Genzyme
G Teva Pharma
L Bayer Vital GmbH
L Bayer Schering AG
L CSL Bering
L EMD Serono
L Fresenius Medical Care
L Genzyme
L Omniamed
L Sanofi Aventis

Ullrich Wuellner, Germany
N

Dan Ziegler, Germany
L, S Meda
L, S Worwag
S Eisai
S Berlin Chemie